ReviewWiener klinische Wochenschrift2010
Hypoxic hepatitis - epidemiology, pathophysiology and clinical management.
Review in Wiener klinische Wochenschrift, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 121 citations in OpenAlex.
- Heart-Liver Interactions: Pathophysiology and Diagnosis of Hypoxic Hepatitis, Congestive Hepatopathy, and Cirrhotic Cardiomyopathy.Diagnostics (Basel, Switzerland) · 2026Review
- Hypoxic hepatitis after cardiac arrest is associated with 30-day mortality, poor neurological outcome and non-occlusive mesenteric ischemia.Resuscitation plus · 2026Article
- Admission Liver Enzyme Elevation Grade for Risk Stratification in Critically Ill Patients: Development and Internal Validation of an Exploratory Prognostic Model.Journal of clinical medicine · 2026Article
- Article
- Prognostic value of preoperative MELD-albumin score in patients undergoing heart transplant.Frontiers in cardiovascular medicine · 2025Article
- [Liver diseases in the intensive care unit].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2024Review
- Causal Relationship between Angina and Hepatic Failure as Revealed by Mendelian Randomization.Journal of clinical medicine · 2024Article
- COVID-19 and liver dysfunction in children: Current views and new hypotheses.World journal of hepatology · 2023Review
- SEC is an antiangiogenic virulence factor that promotesScience advances · 2022Article
- Protective effects of menthol against sepsis-induced hepatic injury: Role of mediators of hepatic inflammation, apoptosis, and regeneration.Frontiers in pharmacology · 2022Article
- Biomarkers of Cholestasis and Liver Injury in the Early Phase of Acute Respiratory Distress Syndrome and Their Pathophysiological Value.Diagnostics (Basel, Switzerland) · 2021Article
- Liver disease in obesity and underweight: the two sides of the coin. A narrative review.Eating and weight disorders : EWD · 2021Review
- Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19-A Retrospective Study.Journal of clinical medicine · 2021Article
- Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives.World journal of clinical cases · 2021Review
- Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect?Annals of intensive care · 2021Article
- Effects of COVID-19 on in-hospital cardiac arrest: incidence, causes, and outcome - a retrospective cohort study.Scandinavian journal of trauma, resuscitation and emergency medicine · 2021Article
- Article
- The Impact of Hypoxic Hepatitis on Clinical Outcomes after Extracorporeal Cardiopulmonary Resuscitation.Journal of clinical medicine · 2020Article
- Association between aminotransferase/alanine aminotransferase ratio and cardiovascular disease mortality in patients on peritoneal dialysis: a multi-center retrospective study.BMC nephrology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxic hepatitis (HH), also known as ischemic hepatitis or shock liver, is characterized by centrilobular liver cell necrosis and sharply increasing serum aminotransferase levels in a clinical setting of cardiac, circulatory or respiratory failure. Nowadays it is recognized as the most frequent cause of acute liver injury with a reported prevalence of up to 10% in the intensive care unit. Patients with HH and vasopressor therapy have a significantly increased mortality risk in the medical intensive care unit population. The main underlying conditions contributing to HH are low cardiac output and septic shock, although a multifactorial etiology is found in the majority of patients. HH causes several complications such as spontaneous hypoglycemia, respiratory insufficiency due to the hepatopulmonary syndrome, and hyperammonemia. HH reverses after successful treatment of the basic HH-causing disease. No specific therapies improving the hepatic function in patients with HH are currently established. Early recognition of HH and its underlying diseases and subsequent initiation of therapy is of central prognostic importance. The purpose of this review is to provide an update on the epidemiology, pathophysiology, and diagnostic and therapeutic options of HH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.